ResultsIQ › Latest results › Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited Q2 FY27 results deck summary
NSE: EMCURE · BSE: 544210
Results deck of 3 Nov 2026, summarised by AI from the filing.
Q2 FY27 revenue ₹28,205 cr, up 24.3% YoY, with EBITDA margin 20.4% and PAT ₹3,251 cr, up 29.3%.
Key takeaways
- Domestic outlook Management expects continued domestic growth over the full year as the strengthened team and portfolio gain traction.
- Domestic acceleration Domestic growth improved from 10% in Q1 FY27 to 12% in Q2 FY27, the second consecutive quarter of double-digit growth.
- International growth International revenue rose 34.5% YoY to ₹16,652 cr, led by Europe, Canada and RoW new launches and approvals.
- Net debt Net debt rose to ₹13,171 cr on Mantra earnout and Gennova consolidation payments.
Emcure Pharmaceuticals Limited Q2 FY27 results
As filed: Revenue ₹2,820 cr (+24% year on year), EBITDA ₹588 cr (+24% year on year), PAT ₹325 cr (+30% year on year), EBITDA margin 20.8% (−13 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹2,580 cr (+23% year on year), EBITDA ₹533 cr (+28% year on year), PAT ₹292 cr (+36% year on year), EBITDA margin 20.6% (+79 bps). Score 66 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 79 bps year on year. Revenue rose ₹479 cr on a year ago, more than the ₹286 cr it added the year before. Share price after the results: −1.6% in 29 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹2,470 cr (+17% year on year), EBITDA ₹480 cr (+19% year on year), PAT ₹244 cr (+24% year on year), EBITDA margin 19.4% (+37 bps). Score 63 of 100, In line with trend. EBITDA margin rose 37 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.7% in 30 days (Nifty 500: −1.5%).
- Q3 FY26: Revenue ₹2,363 cr (+20% year on year), EBITDA ₹493 cr (+39% year on year), PAT ₹231 cr (+53% year on year), EBITDA margin 20.9% (+276 bps). Score 82 of 100, Above trend. EBITDA margin rose 276 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −6.0% in 30 days (Nifty 500: −4.1%).
- Q2 FY26: Revenue ₹2,270 cr (+13% year on year), EBITDA ₹476 cr (+25% year on year), PAT ₹251 cr (+24% year on year), EBITDA margin 21.0% (+199 bps). Score 66 of 100, Above trend. EBITDA margin rose 199 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.2% in 30 days (Nifty 500: −0.2%).
- Q1 FY26: Revenue ₹2,101 cr (+16% year on year), EBITDA ₹417 cr (+24% year on year), PAT ₹215 cr (+41% year on year), EBITDA margin 19.9% (+128 bps). Score 70 of 100, Above trend. EBITDA margin rose 128 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −3.5% in 29 days (Nifty 500: +0.7%).
- Q4 FY25: Revenue ₹2,116 cr, EBITDA ₹403 cr, PAT ₹197 cr, EBITDA margin 19.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹2,116 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +22.2% in 29 days (Nifty 500: +1.4%).
- Q3 FY25: Revenue ₹1,963 cr, EBITDA ₹355 cr, PAT ₹156 cr, EBITDA margin 18.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,963 cr). Scored once a year-earlier consolidated quarter exists.
Past price moves after results do not indicate future moves. Not a recommendation.
Emcure Pharmaceuticals Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (3 Nov 2026), Results deck (3 Nov 2026)
- Q1 FY27: Earnings call (6 Aug 2026), Results deck (6 Aug 2026), Results deck (25 Sep 2026)
- Q4 FY26: Earnings call (5 May 2026), Results deck (5 May 2026), Results deck (12 Jun 2026)
- Q3 FY26: Earnings call (4 Feb 2026)
- Q2 FY26: Earnings call (11 Nov 2025)
- Q1 FY26: Earnings call (7 Aug 2025)
- Q4 FY25: Earnings call (22 May 2025)
- Other events: Investor presentation (6 Nov 2026), Strategy deck (20 Feb 2026), Strategy deck (19 Nov 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.